TEMENOS
16.6.2020 09:09:06 CEST | Business Wire | Press release
Intelligence Sales League Table 2020 (SLT) . Temenos was also named a regional leader in both Europe and Americas. Temenos, with its AI and advanced cloud technology, continues to be the undisputed leader in the main product categories in the IBS League Table with the greatest number of competitors.
Temenos has been ranked as the best-selling core banking system for 15 years, as well as the best-selling vendor for digital banking for the fourth consecutive year. For 21 years running, Temenos has demonstrated consistent leadership, placing in the top two positions for core banking systems. In this year’s Sales League Table, Temenos led in nine categories, including:
- #1 Digital banking and channels with Temenos Infinity, gaining 38 new name deals
- #1 Best-selling core banking system with Temenos Transact, securing 51 new name customer deals
- #1 Retail payments system with 51 new deals for Temenos Payments
- #1 Risk management system, closing 53 new deals with Temenos Financial Crime Mitigation
- #1 Regional Leader in Europe, working with ABN AMRO and challenger banks such as Lunar and Alba
- #1 Regional Leader in Americas, partnering with innovative banks such as CWB Financial Group
- #2 Regional Leader in the Middle-East and Africa with key clients such as Egyptian National Post Organization
- #2 Regional Leader in APAC with innovative clients such as TSB with Temenos Infinity Digital Onboarding and Virgin Money Australia
- #2 Islamic Banking, partnering with the world's largest Islamic bank, Al Rajhi Bank
Max Chuard, Chief Executive Officer, Temenos, said: “It’s a great honor to be recognized as the best-selling banking software provider with the most modern technology across the main product categories of digital, core banking, retail payments, and risk management systems. Now more than ever we see an acceleration in digital and cloud adoption – banks need agile, modern banking technology across the front and back office. We offer our offer our clients, both established banks and new entrants, the winning combination of the richest banking functionality and the most advanced cloud-native, cloud-agnostic technology. We deliver solutions for the ‘New Normal’ that give our clients agility, speed to market, hyper-personalized services at the front end and automation and operational excellence in the back office. The IBS report reconfirms Temenos as global powerhouse and the world’s #1 banking software company and I would like to thank our customers, partners and employees for helping us achieve this exciting milestone.”
IBS’ Sales League Table Panel, said: “2019 was a record-breaking year for our Sales League Table, with nearly 900 validated deals globally and the highest level of vendor participation to-date. Temenos’ success was notable due to achieving #1 positions in the most intensely competitive categories including digital banking, core banking, retail payments and risk management systems. At IBS Intelligence, we are seeing banks re-visiting their digital transformation plans to support their businesses through the current COVID-19 crisis. 2020 will be an interesting year for our industry and we will be continuing to track new deals and trends to support our clients worldwide.”
Temenos continues to relentlessly focus on innovation, investing 20% of its revenue in R&D – more than any other provider in the industry. The IBS Intelligence Sales League Table is the global barometer for sales performance of banking platforms ranging from retail, to private, to Islamic, to digital-only and universal banking. The SLT provides a vital tool to executives in banks for selecting vendors for RFIs and influences vendor selection across conventional and digital banking.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005373/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom